GFAP and perinatal asphyxia: As a first step in moving a panel of neuroprotein biomarkers to the bedside to allow the clinician to selectively identify neonates with mild HIE who would benefit from neuroprotective interventions, we evaluated the serum concentrations of GFAP, UCH-L1, NFL, and Tau proteins in neonates.